Showing 21 - 40 results of 5,845 for search '(( significant decrease decrease ) OR ( significant ((we decrease) OR (a decrease)) ))~', query time: 0.32s Refine Results
  1. 21
  2. 22
  3. 23

    Table 1_Multi-generational adaptation to Solanum nigrum increases reproduction and decreases microbial diversity of Aphis gossypii.docx by Peng Wang (34436)

    Published 2025
    “…Notably, Buchnera and Arsenophonus were two dominant symbiotic bacteria related to metabolism and host adaptability in A. gossypii. The relative abundance of Buchnera in T5 and T10 significantly increased compared to M and T, while the relative abundance of Arsenophonus decreased markedly. …”
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 38

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 39

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 40